Latest News and Press Releases

PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently issued U.S. patent expands PRL-02 IP estate with additional composition of matter...

PITTSBORO, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella” or “the Company”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology...

Propella to Receive Upfront Payment, Regulatory and Sales Milestones, and Royalties Phase 2 Study of CGS-200-5 Reduced Pain by 50% in Patients with Moderate to Severe Osteoarthritis of the Knee ...

Highlights Potential of PRL-02 as Best-in-Class, Next-Generation Androgen Biosynthesis Inhibitor for Treatment of Advanced Prostate Cancer Initial Data from Ongoing Phase 1/2 Study on PRL-02...

ASCO GU Presentation Highlight Nonclinical Data of Next-Generation Androgen Biosynthesis Inhibitor, PRL-02, for Treatment of Advanced Prostate Cancer Company Senior Management Available for...

PITTSBORO, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today...